Abstract: A method is provided, the method including receiving a test result data, wherein said test result data represents a result of a test on a physical specimen, associating said test result data with a standard-of-care data, wherein said standard-of-care data represents a recommended course of action for the condition represented by the test result data, and transforming said specimen data and said standard-of-care data into a human-readable form. A system including a processor is provided, a software adapted to be executed on said processor, said software comprising instructions for receiving a test result data, wherein said test result data represents a result of a test on a physical specimen, associating said test result data with a standard-of-care data, wherein said standard-of-care data represents a recommended course of action for the condition represented by the test result data, and transforming said specimen data and said standard-of-care data into a human-readable form.

Abstract: Methods and compositions for the efficient and accurate determination of susceptibility of a hepatitis C virus (HCV) population to an HCV inhibitor are provided. In certain aspects, the methods involve introducing into a cell a patient derived segment, wherein the cell or the patient derived segment comprises an indicator nucleic acid that produces a detectable signal that is dependent on the HCV; measuring the expression of the indicator gene in the presence of varying concentrations of the HCV inhibitor; determining a standard curve of susceptibility; comparing the IC95 fold change, slope, or maximum inhibition percentage of the HCV population to that of a control HCV population, and determining that the HCV population comprises HCV with a reduced susceptibility to the inhibitor when the IC95 fold change value is increased or the slope and/or maximum inhibition percentage is lower for the HCV population as compared to the control population.

Abstract: Disclosed are methods and systems for the isolation and detection of microbes from a sample. The use of binding agents for isolation of a microbe of interest from a sample are described. In certain embodiments, the methods use ribosome-based and/or bacteriophage-based amplification of the signal in detection of bacteria and other microorganisms. For example, embodiments of the present invention can achieve total amplification of at least 10,000 from a single infected cell.

Abstract: Disclosed herein are methods and systems for the detection of an analyte of interest by an amplified assay. The method and systems of the invention utilize the high specificity of biomolecules that have been coupled to a solid support to further amplify a signal produced by the interaction of a binding agent with the analyte of interest as a means to detect low levels of the analyte of interest present in a sample. In certain embodiments, for immunochemical (for example, ELISA or RIA) or immunofluorescence assays in which a protein to be identified is bound directly or through capture antibodies to a passivated surface, amplification of ˜10,000-fold can be achieved.

Abstract: Systems, methods, and media for laboratory benefit services are disclosed. Embodiments of the present invention provide systems, methods, and media that enhance the quality of health care related services to a patient, thereby enhancing patient care. In an embodiment, the present invention provides systems, methods and media that present a health care provider with information to support a decision, for example, a decision relating to a test, or tests, for a patient. In addition, or in additional embodiment, the present invention provides systems, methods and media that present information relating to a patient's health plan to advantageously facilitate a health care provider's knowledge and use of a patient's health plan information.

Abstract: Whole cell, simultaneous target and drug-target assay using differentially labeled antibodies and flow cytometry. First antibody binds to total target and second antibody binds to the drug binding site of the target, thus drug binding will competitively inhibit the second antibody allowing for a competitive inhibition assay of drug-target binding. The assay allows for whole cell analysis and even analysis of mixed populations of cells, yet provides detailed kinetic assessment of drug activity.

Abstract: Systems, methods, and media for laboratory testing services are disclosed. A request for an electronic form can be received from an electronic device. A customized electronic form can be sent to the electronic device. The electronic form may be customized based at least in part on a healthcare provider associated with the request. At least one laboratory test may be requested to be ordered for at least one patient associated with the healthcare provider. At least one predefined rule may be applied to the requested order to verify that the order is valid. At least one laboratory can be selected to perform the ordered laboratory tests. Specimen collection information may be sent to a collection facility and can be based at least in part on rules or preferences of a lab selected to perform a laboratory test. Customized test reports can be provided to a healthcare provider.

Abstract: Systems, methods, and media for laboratory testing services are disclosed. Medical information can be received from an electronic device. One or more laboratory tests can be recommended based at least in part on the received medical information. For example, if one or more symptoms are received, then one or more laboratory tests may be suggested based at least in part on the received symptoms. As another example, if an order for one or more laboratory tests are received, then one or more additional and/or alternative laboratory tests may be suggested. Suggested laboratory tests can be based on medical symptoms, medical conditions, medical codes, medical history, medications, laboratories, healthcare providers, insurance companies, financial factors, locations, turnaround time, other factors, or a combination thereof. One or more of the suggested laboratory tests can be ordered.

Abstract: Methods and systems for predicting coreceptor tropism are provided. In certain embodiments, the methods may include obtaining the amino acid and/or nucleic acid sequence of at least a portion of the envelope or envelope coding region from a biological sample obtained from a subject; analyzing the amino acid sequence, nucleic acid sequence, or both of the portion of the envelope or envelope coding region using a case based reasoning analysis; and determining the coreceptor tropism. Also provided are systems and computer readable media for utilizing the systems or performing the methods are disclosed.

Abstract: The invention provides methods of measuring and/or quantifying the presence and/or amount of Her-3 and/or Her-3 in a complex in a sample. The invention also provides antibodies specific for Her-3.